ArticleHypertension (Dallas, Tex. : 1979)2001
Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Article in Hypertension (Dallas, Tex. : 1979), 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000542. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity.Internal and emergency medicine · 2016Pooled it
- Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT.Journal of the American Heart Association · 2019Trial
- Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT.Journal of clinical hypertension (Greenwich, Conn.) · 2019Trial
- Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).The American journal of cardiology · 2016Trial
- Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.Journal of the American Society of Hypertension : JASH · 2014Trial
- Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.Journal of clinical hypertension (Greenwich, Conn.) · 2013Trial
- Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.Hypertension (Dallas, Tex. : 1979) · 2013Trial
- Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.Clinical journal of the American Society of Nephrology : CJASN · 2012Trial
- Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2012Trial
- Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.Journal of hypertension · 2010Trial
- Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?Journal of clinical hypertension (Greenwich, Conn.) · 2009Trial
- ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.Archives of internal medicine · 2009Trial
- Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Journal of clinical hypertension (Greenwich, Conn.) · 2008Trial
- Description of pharmacist interventions during physician-pharmacist co-management of hypertension.Pharmacy world & science : PWS · 2008Trial
- Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies.Clinical drug investigation · 2007Trial
- Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Journal of clinical hypertension (Greenwich, Conn.) · 2006Trial
- Characteristics of contemporary patients with hypertension and coronary artery disease.Clinical cardiology · 2004Trial
- Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Journal of clinical hypertension (Greenwich, Conn.) · on this mapTrial
- First-line diuretics versus other classes of antihypertensive drugs for hypertension.The Cochrane database of systematic reviews · 2023Review
- The Self-Fulfilling Process of Clinical Race Correction: The Case of Eighth Joint National Committee Recommendations.Health equity · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
-Diuretics and ss-blockers have been shown to reduce the risk of cardiovascular morbidity and mortality in people with hypertension in long-term clinical trials. No study has compared newer more costly antihypertensive agents (calcium antagonists, ACE inhibitors, and alpha-adrenergic blockers) with diuretics for reducing the incidence of cardiovascular disease in an ethnically diverse group of middle-aged and elderly hypertensive patients. The study is a randomized, double-blind, active-controlled clinical trial designed to determine whether the incidence of the primary outcome, fatal coronary heart disease or nonfatal myocardial infarction, differs between treatment initiation with a diuretic versus each of 3 other antihypertensive drugs. Men and women aged >/=55 years with at least 1 other cardiovascular disease risk factor were randomly assigned to chlorthalidone (12.5 to 25 mg/d), amlodipine (2.5 to 10 mg/d), lisinopril (10 to 40 mg/d), or doxazosin (2 to 8 mg/d) for planned follow-up of 4 to 8 years. This report describes the baseline characteristics of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants. A total of 42 448 participants were randomized from 625 sites in the United States, Canada, Puerto Rico, and the US Virgin Islands. The mean age was 67 years, with 35% aged >/=70 years. Among those randomized, 36% were black, 19% were Hispanic, and 47% were women. The sample includes a high proportion of people with diabetes (36%), patients with existing cardiovascular disease (47%), and smokers (22%). There were no important differences between the randomized treatment groups at baseline. ALLHAT will add greatly to our understanding of the management of hypertension by providing an answer to the following question: are newer antihypertensive agents similar, superior, or inferior to traditional treatment with diuretics?
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.